Cambridge, Massachusetts-based Editas Medicine has appointed Dr Akshay Vaishnaw to its board of directors.
Dr Vaishnaw brings over 30 years of pharmaceuticals experience to the genome editing company, and currently serves as both executive vice president of research and development and chief medical officer at Alnylam Pharmaceuticals.
Prior to joining Alnylam in 2006, he worked in medical research at Biogen and held roles of increasing responsibility before becoming senior director of medical research.
Katrine Bosley, Editas Medicine’s president and chief executive officer, said: “I am delighted to welcome Akshay to our board of directors.
“He has extensive clinical development experience, a passion for scientific excellence, and achieved significant accomplishments as part of the leadership team that has built Alnylam.
“We believe Akshay’s perspective and advice will be invaluable as we continue to advance the organisation and drive innovative new medicines to treat genetic diseases.”